[Should Helicobacter pylori infection be taken into account in the use of nonsteroidal anti-inflammatory agents?].
Bretagne
J F
JF
Service des Maladies de l'Appareil Digestif, Hôpital Pontchaillou, Rennes.
Pagenault
M
M
Bourienne
A
A
Heresbach
D
D
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D051546:Cyclooxygenase 2; D004415:Dyspepsia / Q000139:chemically induced / Q000150:complications; D016481:Helicobacter Infections / Q000150:complications* / Q000201:enzymology / Q000453:epidemiology / Q000503:physiopathology; D016480:Helicobacter pylori; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D008565:Membrane Proteins; D010437:Peptic Ulcer / Q000139:chemically induced / Q000150:complications / Q000503:physiopathology; D010544:Peroxidases / Q000378:metabolism; D015995:Prevalence; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007527:Isoenzymes; D008565:Membrane Proteins; D010544:Peroxidases; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases